CurcuVail® · Curcuma longa root extract
Move freely. Every day.
CurcuVail® is our proprietary turmeric extract, made with a process that makes curcuminoids
fully water-dispersible. In a human pharmacokinetic study it was absorbed
about three times better than standard curcumin 95%, with no added enhancers.
Key Functional Benefits
India grows most of the world’s turmeric, and not all of it is equal. We source from several Indian states with the soil and climate for peak curcuminoid levels, working directly with farmers to harvest at maturity. Sourcing across regions protects year-round supply from a single bad season
- Botanical: Curcuma longa (turmeric) root Standardised to: not less than 35% curcuminoids by HPLC (curcumin, demethoxycurcumin, bisdemethoxycurcumin)
- Solubility: 100% water-dispersible Sensory: no taste, no odour, no staining
- Clean label: no residual solvent, no polysorbates, Non-GMO, self-affirmed GRAS
- Stability: heat stable Grade: food and pharma
CLINICAL EVIDENCE
Four human clinical studies
One pharmacokinetic study and three randomised, placebo-controlled trials.
FORMULATION
No enhancers needed
No piperine or polysorbates added to reach its absorption results.
SENSORY
Invisible in your product
No taste, odour or staining.
What makes it different
Solubility first. Then everything else follows
CORE DIFFERENTIATOR
Fully water-dispersible
Works in beverages and liquid formats where standard curcumin won't.
STUDY 01 · BIOAVAILABILITY
Higher bioavailability, demonstrated in humans.
A pharmacokinetic study compared CurcuVail® with standard 95% curcumin at the same 500 mg dose.
PEAK PLASMA CURCUMIN
82 ng/mL
CurcuVail®
PEAK PLASMA CURCUMIN
36 ng/mL
Standard curcumin
ABSORPTION
3×
Higher absorption
BIOAVAILABILITY
9×
Higher total bioavailability
STUDY SUMMARY
At the same 500 mg dose, CurcuVail® delivered substantially more curcumin into the blood than standard 95% curcumin, without
piperine or any other absorption enhancer.
STUDY DESIGN
Randomised · open-label · two-way crossover
DOSE
500 mg
COMPARISON
CurcuVail® vs 95% curcumin
01
Bioavailability & PK
02
Human Study
03
Randomised trial
04
Clinical study
Four human studies.
Every number published.
CurcuVail® has been studied in four human clinical trials,
each published in peer-reviewed journals.
HUMAN CLINICAL STUDIES
Published human evidence
STUDY SUMMARY
At the same 500 mg dose, CurcuVail® delivered substantially more curcumin into the blood than standard 95% curcumin, without
piperine or any other absorption enhancer.
STUDY 01 · BIOAVAILABILITY
Higher bioavailability, demonstrated in humans.
A pharmacokinetic study compared CurcuVail® with standard 95% curcumin at the same 500 mg dose.
PEAK PLASMA CURCUMIN
82 ng/mL
CurcuVail®
PEAK PLASMA CURCUMIN
36 ng/mL
Standard curcumin
ABSORPTION
3×
Higher absorption
BIOAVAILABILITY
9×
Higher total bioavailability
STUDY SUMMARY
At the same 500 mg dose, CurcuVail® delivered substantially more curcumin into the blood than standard 95% curcumin, without
piperine or any other absorption enhancer.
STUDY DESIGN
Randomised · open-label · two-way crossover
DOSE
500 mg
COMPARISON
CurcuVail® vs 95% curcumin
STUDY SUMMARY
Participants taking CurcuVail® showed significantly greater improvements than placebo in ultrasound NAFLD grading, Fibroscan fibrosis and CAP scores, APRI score, serum ALT and AST, and total cholesterol.
STUDY 02 · LIVER
Randomised, double-blind, placebo-controlled, parallel group.
30 adults with non-alcoholic fatty liver disease (NAFLD) · 250 mg a day · 8 weeks
greater reduction in liver fibrosis score than placebo
5.4x
(−0.91 vs −0.17)
greater reduction in liver fat than placebo
3.9x
(CAP score)
participants whose NAFLD grade improved
26.7% vs 6.7%
(CurcuVail® vs placebo)
greater reduction in serum ALT than placebo
3.7x
serum ALT
STUDY SUMMARY
Participants taking CurcuVail® showed marked improvement in overall clinical score, joint X-ray findings and anti-CCP markers compared with placebo.
CITATION
Clinical study to evaluate the efficacy and safety of CurcuVail® in patients with chronic joint pain (rheumatoid arthritis). European Journal of Pharmaceutical and Medical Research, 2020; 7(3): 282 to 299.
STUDY 03 · JOINT
Prospective, randomised, double-blind, placebo-controlled, parallel.
30 adults with chronic joint pain due to rheumatoid arthritis · 500 mg a day · 12 weeks
improvement in fatigue score vs placebo
84%
fatigue score
improvement in swelling score vs placebo
82%
swelling score
improvement in stiffness score vs placebo
77%
stiffness score
improvement in warmth score vs placebo
76%
warmth score
SUPPORTING RESULTS
Knee X-ray
abnormal findings in 15 of 15 participants at baseline fell to 0 with CurcuVail®, vs 15 to 14 with placebo.
Anti-CCP:
abnormal results fell from 15 to 2 with CurcuVail®, vs 15 to 14 with placebo.
Clinical Global Impression:
9 participants showed marked improvement with CurcuVail®, vs 1 with placebo.
STUDY SUMMARY
By the end of treatment, participants taking CurcuVail® showed significantly greater improvement than placebo across coughing, mucus, wheezing, low-grade fever, chest discomfort and shortness of breath, with improved chest X-ray findings and IgG, IgM and IgE levels.
CITATION
Study to evaluate the efficacy and safety of curcumin capsule in patients with cough due to chronic bronchitis. European Journal of Pharmaceutical and Medical Research, 2019; 6(12): 508 to 519.
STUDY 04 · RESPIRATORY
Prospective, randomised, double-blind, placebo-controlled, parallel
40 adults with cough due to chronic bronchitis · 500 mg a day · 10 weeks
change in coughing frequency score with CurcuVail®
−4.9
(vs −2.8 placebo)
change in mucus score
−4.0
(vs −2.35 placebo)
change in cold symptoms score
−4.2
(vs −2.05 placebo)
change in chest discomfort score
−2.55
(vs −0.35 placebo)
SUPPORTING RESULTS
Knee X-ray
abnormal findings in 15 of 15 participants at baseline fell to 0 with CurcuVail®, vs 15 to 14 with placebo.
Anti-CCP:
abnormal results fell from 15 to 2 with CurcuVail®, vs 15 to 14 with placebo.
Clinical Global Impression:
9 participants showed marked improvement with CurcuVail®, vs 1 with placebo.
01
Bioavailability & PK
02
Human Study
03
Randomised trial
04
Clinical study
Formats and dosage
Made to formulate.
STUDIED DAILY DOSAGE
500 mg
A simple,
studied dose
500 mg a day, as studied.
Daily use
FORMULATION FORMATS
Built for different
product formats.
CurcuVail® can be incorporated across a wide range of consumer and functional product formats.
- Capsules
- Powder sachets
- Beverages
- Bakery & confectionery
- Tablets
- Gummies
- Functional Foods
- Premixes & cosmetics
FORMULATION FLEXIBILITY
From supplements to functional foods.
FROM FIELD TO FORMULATION
We partner with farmers who follow organic and sustainable practices and pay fair prices for their harvest. At our plant, water recycling cuts freshwater use by up to 40%, and spent turmeric biomass becomes compost for partner farms.
F.A.Q.
Explore answers to some of the most common questions about our products, research, formulations, and support.
A proprietary, full-spectrum hydroalcoholic extract of Holy Basil (Ocimum tenuiflorum), standardised for total ursolic acid by USP method.
In a crossover study in 24 healthy adults, CurcuVail® reached a mean peak plasma curcumin of 82 ng/mL vs 36 ng/mL for curcumin 95% at the same 500 mg dose: about 3x higher absorption and 9x higher total bioavailability.
Four published human studies: one bioavailability study and three randomised, double-blind, placebo-controlled trials covering liver, joint and respiratory parameters. Full results are above and in the clinical summary.
Capsules, tablets, powders, gummies, beverages, functional foods, confectionery, bakery, premixes and cosmetics.
Yes. No residual solvents, no polysorbates, no added bioavailability enhancers, Non-GMO and self-affirmed GRAS.
500 mg a day, the dose used in our clinical research.
Certifications
Proud Members of
